Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases.

Lim M, Puttick S, Houston ZH, Thurecht KJ, Kalita-de Croft P, Mahler S, Rose SE, Jeffree RL, Mazzieri R, Dolcetti R, Lakhani SR, Saunus JM.

Int J Mol Sci. 2019 Mar 14;20(6). pii: E1280. doi: 10.3390/ijms20061280. Review.

2.

Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance.

Budhwani M, Mazzieri R, Dolcetti R.

Front Oncol. 2018 Aug 21;8:322. doi: 10.3389/fonc.2018.00322. eCollection 2018. Review.

3.

Humanization of bone and bone marrow in an orthotopic site reveals new potential therapeutic targets in osteosarcoma.

Wagner F, Holzapfel BM, McGovern JA, Shafiee A, Baldwin JG, Martine LC, Lahr CA, Wunner FM, Friis T, Bas O, Boxberg M, Prodinger PM, Shokoohmand A, Moi D, Mazzieri R, Loessner D, Hutmacher DW.

Biomaterials. 2018 Jul;171:230-246. doi: 10.1016/j.biomaterials.2018.04.030. Epub 2018 Apr 16.

PMID:
29705656
4.

Immune system augmentation via humanization using stem/progenitor cells and bioengineering in a breast cancer model study.

Shafiee A, McGovern JA, Lahr CA, Meinert C, Moi D, Wagner F, Landgraf M, De-Juan-Pardo E, Mazzieri R, Hutmacher DW.

Int J Cancer. 2018 Sep 15;143(6):1470-1482. doi: 10.1002/ijc.31528. Epub 2018 May 7.

5.

Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy.

Zeng B, Middelberg AP, Gemiarto A, MacDonald K, Baxter AG, Talekar M, Moi D, Tullett KM, Caminschi I, Lahoud MH, Mazzieri R, Dolcetti R, Thomas R.

J Clin Invest. 2018 May 1;128(5):1971-1984. doi: 10.1172/JCI96791. Epub 2018 Apr 9.

6.

B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity.

McKee SJ, Tuong ZK, Kobayashi T, Doff BL, Soon MS, Nissen M, Lam PY, Keane C, Vari F, Moi D, Mazzieri R, Leggatt G, Gandhi MK, Mattarollo SR.

Oncoimmunology. 2017 Dec 18;7(2):e1393599. doi: 10.1080/2162402X.2017.1393599. eCollection 2018.

7.

Interleukin-23 regulates interleukin-17 expression in wounds, and its inhibition accelerates diabetic wound healing through the alteration of macrophage polarization.

Lee J, Rodero MP, Patel J, Moi D, Mazzieri R, Khosrotehrani K.

FASEB J. 2018 Apr;32(4):2086-2094. doi: 10.1096/fj.201700773R. Epub 2018 Jan 5.

PMID:
29208701
8.

Translational Significance for Tumor Metastasis of Tumor-Associated Macrophages and Epithelial-Mesenchymal Transition.

Song W, Mazzieri R, Yang T, Gobe GC.

Front Immunol. 2017 Sep 13;8:1106. doi: 10.3389/fimmu.2017.01106. eCollection 2017. Review.

9.

The duality of macrophage function in chronic lymphocytic leukaemia.

Chen YCE, Mapp S, Blumenthal A, Burgess ML, Mazzieri R, Mattarollo SR, Mollee P, Gill D, Saunders NA.

Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):176-182. doi: 10.1016/j.bbcan.2017.03.006. Epub 2017 Mar 24. Review.

PMID:
28347751
10.

Engineering a humanized bone organ model in mice to study bone metastases.

Martine LC, Holzapfel BM, McGovern JA, Wagner F, Quent VM, Hesami P, Wunner FM, Vaquette C, De-Juan-Pardo EM, Brown TD, Nowlan B, Wu DJ, Hutmacher CO, Moi D, Oussenko T, Piccinini E, Zandstra PW, Mazzieri R, Lévesque JP, Dalton PD, Taubenberger AV, Hutmacher DW.

Nat Protoc. 2017 Apr;12(4):639-663. doi: 10.1038/nprot.2017.002. Epub 2017 Mar 2.

PMID:
28253234
11.

Increased FcγRIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients.

Burgess M, Mapp S, Mazzieri R, Cheung C, Chambers L, Mattarollo SR, Mollee P, Gill D, Saunders NA.

Oncogene. 2017 Apr 27;36(17):2366-2376. doi: 10.1038/onc.2016.387. Epub 2016 Oct 17.

PMID:
27748757
12.

Angiopoietin 2 expression in the cornea and its control of corneal neovascularisation.

Ferrari G, Giacomini C, Bignami F, Moi D, Ranghetti A, Doglioni C, Naldini L, Rama P, Mazzieri R.

Br J Ophthalmol. 2016 Jul;100(7):1005-1010. doi: 10.1136/bjophthalmol-2015-307901. Epub 2016 May 4.

PMID:
27146154
13.

Transcriptomic analysis of monocytes and macrophages derived from CLL patients which display differing abilities to respond to therapeutic antibody immune complexes.

Burgess M, Ellis JJ, Mapp S, Mollee P, Mazzieri R, Mattarollo SR, Gill D, Saunders NA.

Genom Data. 2015 Nov 11;7:4-6. doi: 10.1016/j.gdata.2015.11.010. eCollection 2016 Mar.

14.

Urokinase Receptor Promotes Skin Tumor Formation by Preventing Epithelial Cell Activation of Notch1.

Mazzieri R, Pietrogrande G, Gerasi L, Gandelli A, Colombo P, Moi D, Brombin C, Ambrosi A, Danese S, Mignatti P, Blasi F, D'Alessio S.

Cancer Res. 2015 Nov 15;75(22):4895-909. doi: 10.1158/0008-5472.CAN-15-0378. Epub 2015 Nov 2.

15.

Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy.

Ronca R, Giacomini A, Di Salle E, Coltrini D, Pagano K, Ragona L, Matarazzo S, Rezzola S, Maiolo D, Torrella R, Moroni E, Mazzieri R, Escobar G, Mor M, Colombo G, Presta M.

Cancer Cell. 2015 Aug 10;28(2):225-39. doi: 10.1016/j.ccell.2015.07.002.

16.
17.

Targeted genome editing in human repopulating haematopoietic stem cells.

Genovese P, Schiroli G, Escobar G, Tomaso TD, Firrito C, Calabria A, Moi D, Mazzieri R, Bonini C, Holmes MC, Gregory PD, van der Burg M, Gentner B, Montini E, Lombardo A, Naldini L.

Nature. 2014 Jun 12;510(7504):235-240. doi: 10.1038/nature13420. Epub 2014 May 28.

18.

Genetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progression.

Escobar G, Moi D, Ranghetti A, Ozkal-Baydin P, Squadrito ML, Kajaste-Rudnitski A, Bondanza A, Gentner B, De Palma M, Mazzieri R, Naldini L.

Sci Transl Med. 2014 Jan 1;6(217):217ra3. doi: 10.1126/scitranslmed.3006353.

19.

A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice.

Zonari E, Pucci F, Saini M, Mazzieri R, Politi LS, Gentner B, Naldini L.

Blood. 2013 Jul 11;122(2):243-52. doi: 10.1182/blood-2012-08-449306. Epub 2013 Mar 13.

20.

Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.

Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L, De Palma M.

Cancer Cell. 2011 Apr 12;19(4):512-26. doi: 10.1016/j.ccr.2011.02.005.

21.

Perturbation of transforming growth factor (TGF)-beta1 association with latent TGF-beta binding protein yields inflammation and tumors.

Yoshinaga K, Obata H, Jurukovski V, Mazzieri R, Chen Y, Zilberberg L, Huso D, Melamed J, Prijatelj P, Todorovic V, Dabovic B, Rifkin DB.

Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18758-63. doi: 10.1073/pnas.0805411105. Epub 2008 Nov 20.

22.

Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis.

De Palma M, Mazzieri R, Politi LS, Pucci F, Zonari E, Sitia G, Mazzoleni S, Moi D, Venneri MA, Indraccolo S, Falini A, Guidotti LG, Galli R, Naldini L.

Cancer Cell. 2008 Oct 7;14(4):299-311. doi: 10.1016/j.ccr.2008.09.004.

23.

Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer.

Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, Mazzieri R, Doglioni C, Naldini L.

Blood. 2007 Jun 15;109(12):5276-85. Epub 2007 Feb 27.

24.

A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts.

Mazzieri R, Furlan F, D'Alessio S, Zonari E, Talotta F, Verde P, Blasi F.

Oncogene. 2007 Feb 1;26(5):725-32. Epub 2006 Jul 31.

PMID:
16878153
25.

Hypomorphic mutation of the TALE gene Prep1 (pKnox1) causes a major reduction of Pbx and Meis proteins and a pleiotropic embryonic phenotype.

Ferretti E, Villaescusa JC, Di Rosa P, Fernandez-Diaz LC, Longobardi E, Mazzieri R, Miccio A, Micali N, Selleri L, Ferrari G, Blasi F.

Mol Cell Biol. 2006 Aug;26(15):5650-62.

26.

An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration.

Mazzieri R, D'Alessio S, Kenmoe RK, Ossowski L, Blasi F.

Mol Biol Cell. 2006 Jan;17(1):367-78. Epub 2005 Nov 2.

27.

Expression of truncated latent TGF-beta-binding protein modulates TGF-beta signaling.

Mazzieri R, Jurukovski V, Obata H, Sung J, Platt A, Annes E, Karaman-Jurukovska N, Gleizes PE, Rifkin DB.

J Cell Sci. 2005 May 15;118(Pt 10):2177-87. Epub 2005 May 3.

28.

The urokinase receptor and the regulation of cell proliferation.

Mazzieri R, Blasi F.

Thromb Haemost. 2005 Apr;93(4):641-6.

PMID:
15841307
29.

Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein.

Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R, Charbonneau NL, Reinhardt DP, Rifkin DB, Sakai LY.

J Biol Chem. 2003 Jan 24;278(4):2750-7. Epub 2002 Nov 11.

30.

Measurement of active TGF-beta generated by cultured cells.

Mazzieri R, Munger JS, Rifkin DB.

Methods Mol Biol. 2000;142:13-27. Review. No abstract available.

PMID:
10806610
31.

Proteolytic control of growth factor availability.

Rifkin DB, Mazzieri R, Munger JS, Noguera I, Sung J.

APMIS. 1999 Jan;107(1):80-5. Review.

PMID:
10190283
32.

[Peripartum cardiomyopathy. A critical analysis of immunosuppression].

Rached H, de Cleva R, Pinheiro R, Mekhitarian PG, Mazzieri R.

Arq Bras Cardiol. 1998 Apr;70(4):279-81. Review. Portuguese.

PMID:
9687629
33.

Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.

Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P.

EMBO J. 1997 May 1;16(9):2319-32.

34.

Latent transforming growth factor-beta: structural features and mechanisms of activation.

Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB.

Kidney Int. 1997 May;51(5):1376-82. Review.

35.

Plasminogen/plasminogen activator and growth factor activation.

Rifkin DB, Gleizes PE, Harpel J, Nunes I, Munger J, Mazzieri R, Noguera I.

Ciba Found Symp. 1997;212:105-15; discussion 116-8. Review.

PMID:
9524766
36.

TGF-beta latency: biological significance and mechanisms of activation.

Gleizes PE, Munger JS, Nunes I, Harpel JG, Mazzieri R, Noguera I, Rifkin DB.

Stem Cells. 1997;15(3):190-7. Review.

38.

Tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells.

Seghezzi G, Marelli R, Mandriota SJ, Nolli ML, Mazzieri R, Mignatti P.

J Cell Physiol. 1996 Nov;169(2):300-8.

PMID:
8908197
39.

Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells.

Mandriota SJ, Seghezzi G, Vassalli JD, Ferrara N, Wasi S, Mazzieri R, Mignatti P, Pepper MS.

J Biol Chem. 1995 Apr 28;270(17):9709-16.

40.

Favorable effects of immunosuppressive therapy in children with dilated cardiomyopathy and active myocarditis.

Camargo PR, Snitcowsky R, da Luz PL, Mazzieri R, Higuchi ML, Rati M, Stolf N, Ebaid M, Pileggi F.

Pediatr Cardiol. 1995 Mar-Apr;16(2):61-8.

PMID:
7784236
41.

Assignment of the human urokinase receptor gene (PLAUR) to 19q13.

Vagnarelli P, Raimondi E, Mazzieri R, De Carli L, Mignatti P.

Cytogenet Cell Genet. 1992;60(3-4):197-9.

PMID:
1324136
42.
43.

[Tuberous sclerosis associated with left ventricle rhabdomyoma].

De Almeida SL, Silva ML, Mazzieri R, De Souza JM, De Oliveira SA.

Arq Bras Cardiol. 1990 Dec;55(6):381-3. Portuguese.

PMID:
2095119
44.

[Early surgical correction of the left coronary artery with origin at the pulmonary trunk. Late development].

de Almeida SL, Mazzieri R, Berlinck MF, Souza JM, de Oliveira SA.

Arq Bras Cardiol. 1990 Nov;55(5):319-23. Portuguese.

PMID:
2090076
45.

[Immunosuppressive drugs for the treatment of active myocarditis in children. Hemodynamic evaluation].

Camargo PR, Mazzieri R, Snitcowsky R, Ratti M, Costa R, Higuchi ML, Albuquerque AM, Meneghetti C, Ebaid M, Pileggi F.

Arq Bras Cardiol. 1990 Nov;55(5):295-9. Portuguese.

PMID:
2090072
46.

Correlation between gallium-67 imaging and endomyocardial biopsy in children with severe dilated cardiomyopathy.

Camargo PR, Mazzieri R, Snitcowsky R, Higuchi ML, Meneghetti JC, Soares Júnior J, Fiorelli A, Ebaid M, Pileggi F.

Int J Cardiol. 1990 Sep;28(3):293-7.

PMID:
2210893
47.

[Histologic response of the myocardium to various immunosuppressor schedules in patients with dilated cardiomyopathy and diagnosis of myocarditis at endomyocardial biopsy].

Higuchi Mde L, Camargo PR, Aiello VD, Mazzieri R, Snitcowsky R, Fiorelli A, Ebaid M, Pileggi F.

Arq Bras Cardiol. 1990 May;54(5):319-22. Portuguese.

PMID:
2288519
48.

[Primary rhabdomyosarcoma of the heart in children. A case report].

Cavalini JF, Camargo PR, Mazzieri R, Camarano GP, Falzoni R, Odone Filho V, Ebaid M.

Arq Bras Cardiol. 1990 Jan;54(1):49-52. Portuguese.

PMID:
2264771
49.

[Endomyocardial biopsy and myocardial imaging with 67-gallium in the diagnosis of active myocarditis in children with dilated myocardiopathy].

Camargo PR, Mazzieri R, Snitcowsky R, Meneguetti C, Soares Júnior J, Higuchi Mde L, Ebaid M, Pileggi F.

Arq Bras Cardiol. 1990 Jan;54(1):27-31. Portuguese.

PMID:
2264767
50.

[Hypoplasia of the abdominal aorta. A case report].

Assad RS, Rabello RR, Martins JR, Mazzieri R, de Oliveira SA.

Arq Bras Cardiol. 1987 Apr;48(4):241-4. Portuguese. No abstract available.

PMID:
3446122

Supplemental Content

Loading ...
Support Center